Burcon NutraScience (BU) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
13 Jan, 2026Executive summary
Announced a transformative shift to direct market reach and control over production, addressing a long-standing supply challenge.
Strategic alliance formed with a buying group led by a board member to acquire and retrofit a production facility, enabling direct operation and sales of the protein portfolio.
Achieved first commercial production of canola protein isolate and expanded customer pipeline with over 80 prospects, many in late-stage evaluation.
Launched PurateinⓇ canola protein into the egg replacement market and completed a process scale-up for a contract research customer.
Welcomed a new director with extensive food industry experience, supporting go-to-market and commercialization efforts.
Financial highlights
Cash balance declined from CAD 4.2 million in March to CAD 1 million, with access to an additional CAD 3 million from a loan facility.
Revenue for the quarter was $40,000, down from $184,000 in the same quarter last year, reflecting a shift from royalty to product and service sales.
Net loss widened to $2.4 million ($0.02 per share) from $1.4 million ($0.01 per share) year-over-year.
Gross R&D expenses increased to $1.3 million from $0.9 million, driven by commercialization and patent costs.
Rights offering launched to raise up to CAD 12 million, supporting operations through to cash flow positive and aligning with facility acquisition.
Outlook and guidance
Commercial production at the new facility targeted for the first half of 2025, with initial supply contracts expected in Q3 and recurring revenue in Q4.
Profitability anticipated in calendar 2026, with future margin expansion through licensing and technology sales.
Management remains focused on ramping production, launching new product lines, and converting prospects into recurring sales.
Sunflower protein expected to ramp up later than other proteins, with significant adoption projected in late year two into year three.
Committed to a capital-light business plan and pursuing opportunities to accelerate profitability.
Latest events from Burcon NutraScience
- Revenue up 273% year-over-year to CAD 1.3M; new financing to support capacity expansion.BU
Q1 2027 - Revenue up 494% year-over-year as commercial protein sales accelerate and customer base grows.BU
Q4 2026 - Q3 revenue up 1100% year-over-year to $740,000, with new financing fueling expansion.BU
Q3 2026 - Quarterly revenue up 783% with strong commercial traction and new financing secured.BU
Q2 2026 - 44% revenue growth, first commercial protein sales, and 2025–2026 growth targets reaffirmed.BU
Q1 2026 - $9.4M raised, Galesburg facility acquired, revenue doubled, 50%+ gross margin expected.BU
Q4 2025 - First commercial protein sales and strong demand set the stage for profitability in 2025.BU
Q1 2025 - Commercial hemp and canola protein launches, reduced losses, and growth expected in late 2024.BU
Q4 2024 - Secured funding and a U.S. facility, targeting profitability by 2026 with strong product demand.BU
Q3 2025